文献速递关节外科

静态与活动型间隔物:感染病原体类型是否影响治疗成功率?

Static Versus Articulating Spacer: Does Infectious Pathogen Type Affect Treatment Success?
PubMed 文献 · Clin Orthop Relat Res · 2024-04-25

本研究纳入2014年1月至2022年1月接受抗生素间隔物治疗的277例膝关节假体周围感染(PJI)患者,最终分析246例(静态间隔物61例,活动型间隔物185例)。中位随访至少1年,调整协变量后静态与活动型间隔物的无失败生存率无显著差异(HR 1.45,95%CI 0.94-2.22,p=0.09),且间隔物类型与病原体类型之间无显著交互作用。作者认为感染病原体可能不是选择间隔物类型的重要考虑因素。

要点

  • 静态与活动型间隔物在无失败生存率上无显著差异(HR 1.45,95%CI 0.94-2.22,p=0.09)。
  • 间隔物类型与病原体类型(葡萄球菌 vs 非葡萄球菌)交互作用p=0.14,无显著差异。
  • 间隔物类型与治疗难度(难治 vs 非难治)交互作用p=0.20,无显著差异。

核心结论

  • 静态与活动型间隔物在无失败生存率上无显著差异,且无足够证据表明间隔物类型与治疗失败的关系因病原体类型而异,提示感染病原体可能不是选择间隔物类型的重要考虑因素。
  • 作者建议进一步研究应阐明哪些患者因素对术者选择间隔物类型最具影响力。

研究设计与样本

  • 回顾性队列研究,纳入2014年1月至2022年1月在本机构接受膝关节PJI间隔物治疗的277例患者,最终分析246例(静态间隔物61例,活动型间隔物185例)。
  • 主要结局为无失败生存率,失败定义为再次手术、再感染、感染导致死亡或完成第一阶段术后抗生素疗程后至少1年时慢性抗生素使用,以先发生者为准。
  • 采用Cox比例风险模型比较静态与活动型间隔物,并纳入间隔物类型与病原体类型的交互项。

主要发现

  • 调整协变量后,静态间隔物相对于活动型间隔物(参照)的病因特异性风险比无显著差异(HR 1.45,95%CI 0.94-2.22,p=0.09)。
  • 葡萄球菌感染中静态 vs 活动型间隔物的HR为0.37(95%CI 0.15-0.91),非葡萄球菌感染中HR为0.79(95%CI 0.49-1.28),交互作用p=0.14。
  • 难治性感染中静态 vs 活动型间隔物的HR为0.37(95%CI 0.14-0.99),非难治性感染中HR为0.75(95%CI 0.47-1.20),交互作用p=0.20。

关键数值与推荐

  • 难治性病原体包括耐甲氧西林金黄色葡萄球菌、甲氧西林敏感金黄色葡萄球菌、棒状杆菌属、分枝杆菌属、肠球菌属及其他革兰阴性杆菌。
  • 再感染由治疗医师根据肌肉骨骼感染学会(MSIS)指南判定,包括感染实验室指标、培养和临床感染征象的评估。

临床怎么用

  • 本机构医师通常对就诊较晚或慢性感染使用间隔物,间隔物选择由术者偏好决定,骨缺损较多和软组织覆盖较差时更常使用静态间隔物。

局限性

  • 本研究为回顾性研究,间隔物选择由术者偏好决定,可能存在选择偏倚。
  • 31例患者(静态间隔物8例,活动型间隔物23例)因失访或数据不完整被排除。
  • 作者指出需要进一步研究以阐明哪些患者因素对术者选择间隔物类型最具影响力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with a static or an articulating antibiotic-containing spacer is a common strategy for treating periprosthetic joint infection (PJI), yet many patients have persistent infections after spacer treatment. Although previous studies have compared the efficacy of a static and articulating spacer for treating PJI, few studies have assessed infection control from the time of spacer implantation, or they defined treatment failure as including reinfection, reoperation, or chronic suppressive therapy. Additionally, few studies have examined whether there is an interaction between spacer and pathogen type with respect to treatment success. QUESTIONS/PURPOSES: (1) Is there a difference in failure-free survival (defined as no reoperation, reinfection, or suppressive antibiotic therapy) between static and articulating spacers after spacer implantation for PJI? (2) Did the relationship between spacer type and failure-free survival differ by pathogen type (staphylococcal versus nonstaphylococcal and difficult-to-treat [including methicillin-resistant Staphylococcus aureus, methicillin-susceptible S. aureus , Corynebacterium, Mycobacterium, Enterococcus spp , and other gram-negative bacterium] versus not-difficult-to-treat organisms)? METHODS: Between January 2014 and January 2022, a convenience sample of 277 patients was identified as having knee PJIs treated with an articulating (75% [208 of 277]) or static (25% [69 of 277]) antibiotic spacer and potentially eligible for this study. During that time, providers at our institution generally used spacers for later-presenting or chronic infections. Spacer choice was determined by surgeon preference, with static spacers used more often in instances of higher bone loss and poor soft tissue coverage. Thirty-one patients (8 static and 23 articulating spacers) were considered lost to follow-up or had incomplete datasets and were excluded from the analysis, resulting in a final analysis cohort of 246 patients: 25% (61 of 246) received a static spacer and 75% (185 of 246) received an articulating spacer. The mean ± standard deviation age of patients was 66 ± 9.9 years, BMI was 33.3 ± 6.9 kg/m 2 , and Elixhauser score was 18.1 ± 16.9. Demographic and clinical characteristics were similar between the two groups. Pathogen type was collected and categorized as staphylococcal versus nonstaphylococcal , and difficult-to-treat (including methicillin-resistant Staphylococcus aureus , methicillin-susceptible S. aureus , Corynebacterium, Mycobacterium, Enterococcus spp , and other gram-negative bacterium) versus not-difficult-to-treat, as defined by an infectious disease physician. Other variables we collected included sex, age, American Society of Anesthesiologists classification, BMI, and Elixhauser score. The primary outcome of interest was failure-free survival, which was a composite time-to-event outcome, with failure defined as reoperation, reinfection, death owing to infection, or chronic antibiotic use at a minimum of 1 year after the completion of the patient's Stage 1 postoperative antibiotic course, whichever came first. Reinfection was determined by the treating physicians in accordance with the Musculoskeletal Infection Society guidelines and included an evaluation of infectious laboratory values, cultures, and clinical signs of infection. We compared static and articulating spacers using a Cox proportional hazards model, with spacer type as the primary predictor variable. We compared staphylococcal versus nonstaphylococcal and difficult-to-treat versus not-difficult-to-treat infections by running additional models with interaction terms between spacer type and pathogen type. RESULTS: No difference was observed in the cause-specific hazard ratio for static versus articulating (reference) spacers (HR 1.45 [95% confidence interval 0.94 to 2.22]; p = 0.09), after adjusting for covariates. Additionally, no difference in the association between spacer type and failure-free survival was found between pathogen types or treatment difficulty after evaluating interactions (staphylococcal HR 0.37 [95% CI 0.15 to 0.91], nonstaphylococcal HR 0.79 [95% CI 0.49 to 1.28]; p value for interaction = 0.14; difficult-to-treat HR 0.37 [95% CI 0.14 to 0.99], not-difficult-to-treat HR 0.75 [95% CI 0.47 to 1.20]; p value for interaction = 0.20). CONCLUSION: The lack of a difference in failure-free survival and insufficient evidence of a difference in the association between spacer type and treatment failure by pathogen type suggests that infectious organism may not be an important consideration in the decision about spacer treatment type. Further studies should aim to elucidate which patient factors are the most influential in surgeon decision-making when choosing a spacer type in patients with PJI of the knee.Level of Evidence Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Grant C, Chang J, Poehlein E, et al. Static Versus Articulating Spacer: Does Infectious Pathogen Type Affect Treatment Success? Clin Orthop Relat Res. 2024. PMID: 38662933. doi:10.1097/CORR.0000000000003075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。